Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach

International Journal of Pharmaceutics

Volumn 399, Issue 1-2, 2010, Pages 94-101

  Onoue, Satomi ^a   Sato, Hideyuki ^a   Ogawa, Kumiko ^a   Kawabata, Yohei ^a   Mizumoto, Takahiro ^b,c   Yuminoki, Kayo ^d   Hashimoto, Naofumi ^d   Yamada, Shizuo ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ILS Inc   (Japan)

^c American Peptide Company   (United States)

^d SETSUNAN UNIVERSITY   (Japan)

Author keywords

Amorphous; Cyclosporine A; Dissolution; FT IR; Solid dispersion

Indexed keywords

CYCLOSPORIN A; ZIRCONIUM OXIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CAPILLARY ELECTROPHORESIS; CONFORMATIONAL TRANSITION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; INFRARED SPECTROSCOPY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VISCOSITY; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG CARRIERS; DRUG COMPOUNDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; MICROSCOPY, ELECTRON, SCANNING; PHYSICOCHEMICAL PHENOMENA; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES;

EID: 77956880320     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.08.007     Document Type: Article

References (36)

1. Alexander A.G., Barnes N.C., Kay A.B. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992, 339:324-328.
2. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
3. Beauchesne P.R., Chung N.S., Wasan K.M. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev. Ind. Pharm. 2007, 33:211-220.
4. Bertacche V., Pini E., Stradi R., Stratta F. Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy. J. Pharm. Sci. 2006, 95:159-166.
5. Bhugra C., Pikal M.J. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci. 2008, 97:1329-1349.
6. Borel J.F., Feurer C., Gubler H.U., Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976, 6:468-475.
7. Calderon E., Lockey R.F., Bukantz S.C., Coffey R.G., Ledford D.K. Is there a role for cyclosporine in asthma?. J. Allergy Clin. Immunol. 1992, 89:629-636.
8. Chimalakonda A.P., Shah R.B., Mehvar R. High-performance liquid chromatographic analysis of cyclosporin A in rat blood and liver using a commercially available internal standard. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2002, 772:107-114.
9. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 1971, 60:1281-1302.
10. Czogalla A. Oral cyclosporine A - the current picture of its liposomal and other delivery systems. Cell. Mol. Biol. Lett. 2009, 14:139-152.
11. Friesen D.T., Shanker R., Crew M., Smithey D.T., Curatolo W.J., Nightingale J.A. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm. 2008, 5:1003-1019.
12. Hancock B.C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 2000, 17:397-404.
13. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., Weimar W., van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 2003, 74:245-254.
14. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 1991, 43:287-289.
15. Johnston A., Marsden J.T., Hla K.K., Henry J.A., Holt D.W. The effect of vehicle on the oral absorption of cyclosporin. Br. J. Clin. Pharmacol. 1986, 21:331-333.
16. Kovarik J.M., Mueller E.A., van Bree J.B., Tetzloff W., Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 1994, 83:444-446.
17. Lallemand F., Perottet P., Felt-Baeyens O., Kloeti W., Philippoz F., Marfurt J., Besseghir K., Gurny R. A water-soluble prodrug of cyclosporine A for ocular application: a stability study. Eur. J. Pharm. Sci. 2005, 26:124-129.
18. Lechuga-Ballesteros D., Abdul-Fattah A., Stevenson C.L., Bennett D.B. Properties and stability of a liquid crystal form of cyclosporine - the first reported naturally occurring peptide that exists as a thermotropic liquid crystal. J. Pharm. Sci. 2003, 92:1821-1831.
19. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
20. Lindholm A., Henricsson S., Lind M., Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur. J. Clin. Pharmacol. 1988, 34:461-464.
21. Lobenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000, 50:3-12.
22. Miyake K., Arima H., Irie T., Hirayama F., Uekama K. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol. Pharm. Bull. 1999, 22:66-72.
23. Niwa T., Hashimoto N. Novel technology to prepare oral formulations for preclinical safety studies. Int. J. Pharm. 2008, 350:70-78.
24. Nizankowska E., Soja J., Pinis G., Bochenek G., Sladek K., Domagala B., Pajak A., Szczeklik A. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur. Respir. J. 1995, 8:1091-1099.
25. Onoue S., Iwasa S., Kojima T., Katoh F., Debari K., Koh K., Matsuda Y., Yajima T. Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J. Chromatogr. A 2006, 1109:167-173.
26. Onoue S., Sato H., Kawabata Y., Mizumoto T., Hashimoto N., Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J. Control. Release 2009, 138:16-23.
27. Parrott E.L., Braun R.J. Determination of micelle size by the Stokes-Einstein equation. Chem. Pharm. Bull. 1973, 21:1042-1046.
28. Ren F., Jing Q., Tang Y., Shen Y., Chen J., Gao F., Cui J. Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Dev. Ind. Pharm. 2006, 32:967-972.
29. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88:1058-1066.
30. Tantishaiyakul V., Kaewnopparat N., Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm. 1999, 181:143-151.
31. Tjia J.F., Webber I.R., Back D.J. Cyclosporin metabolism by the gastrointestinal mucosa. Br. J. Clin. Pharmacol. 1991, 31:344-346.
32. Underwood S.L., McMillan S., Reeves R., Hunt J., Brealey C.J., Webber S., Foster M., Sargent C.A. Effects of cyclosporin A administered into the airways against antigen-induced airway inflammation and hyperreactivity in the rat. Eur. J. Pharmacol. 2001, 420:165-173.
33. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12:1068-1075.
34. Venkataram S., Awni W.M., Jordan K., Rahman Y.E. Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. J. Pharm. Sci. 1990, 79:216-219.
35. Wu C.Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005, 22:11-23.
36. Zijlstra G.S., Rijkeboer M., Jan van Drooge D., Sutter M., Jiskoot W., van de Weert M., Hinrichs W.L., Frijlink H.W. Characterization of a cyclosporine solid dispersion for inhalation. AAPS J. 2007, 9:E190-199.